Lung Cancer

In combination with the standard front-line chemotherapy regimen of carboplatin and etoposide, the addition of atezolizumab (Tecentriq) significantly prolonged survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

The Society for Immunotherapy of Cancer (SITC) announced a new partnership to raise awareness of and participation in the Lung Cancer Registry, an initiative led by research and patient advocacy organizations, the Bonnie J. Addario Lung Cancer Foundation (ALCF), American Lung Association’s LUNG FORCE and the International Association for the Study of Lung Cancer.

The Bonnie J. Addario Lung Cancer Foundation (ALCF) is partnering with ALK Positive, an online community of over 1,200 members worldwide dealing with ALK-positive lung cancer, to encourage Lung Cancer Registry membership.

The Food and Drug Administration (FDA) granted priority review to pembrolizumab (Keytruda) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

The phase I open-label LIBRETTO-001 clinical trial is currently testing LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other tumors with increased RET activity.

The FDA granted breakthrough therapy designation to the oral agent LOXO-292 for the treatment of RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC).

The Bonnie J. Addario Lung Cancer Foundation (ALCF) and the EGFR Resisters, a patient-driven community of people living with epidermal growth factor receptor (EGFR) positive lung cancer and their loved ones, are working together to raise funds and increase awareness of projects that benefit the EGFR community.

The trial that led to national screening guidelines—which recommend screening based on age and smoking history—did not include fair representation from all racial/ethnic groups.

Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.

The FDA has granted a full approval to the combination use of pembrolizumab (Keytruda) plus standard chemotherapy in the first-line setting for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).

The FDA has granted an accelerated approval to nivolumab (Opdivo) for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy and 1 other line of therapy.

Even among former smokers who have not smoked in more than 15 years, there is more than a minimal risk of lung cancer.

The partners will collaborate to empower the lung cancer community through educational efforts.

The FDA granted a priority review to the anti-PD-1 agent pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.

Key recommendations from LUNGevity's Expanded Eligibility working group were published in the Journal of Thoracic Oncology.

Next-generation sequencing (NGS) in metastatic non–small cell lung cancer (NSCLC) can save Center for Medicare and Medicaid Services (CMS) payers $1.4 million to $2.1 million.

The FDA has granted breakthrough therapy designation to the kinase inhibitor crizotinib (Xalkori) for two indications.

CE lesson worth 1 contact hour that is intended to advanced practice nurses, registered nurses, and other healthcare professionals who care for patients with cancer.

The FDA has granted a priority review to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the frontline treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).

Helena A. Yu, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explains the implications of the approval of osimertinib as the frontline standard of care for patients with EGFR-mutant non–small cell lung cancer.

The FDA has granted a priority review for frontline use of the PD-1 inhibitor pembrolizumab (Keytruda) in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.

The FDA has approved osimertinib (Tagrisso) for frontline use in patients with non–small cell lung cancer (NSCLC) who have EGFR-mutated tumors.

The FDA has granted priority review to a supplemental biologics license application for nivolumab (Opdivo) to be used to treat patients with small cell lung cancer who have already had two or more lines of therapy, and whose disease has continued to progress.

Significant improvements over chemotherapy alone makes frontline pembrolizumab (Keytruda) treatment a clear choice.